When the Trump administration rolled out its drug pricing blueprint in May 2018, framing it as its plan to make good on one of the president’s signature campaign promises, it promised to shake up how Americans pay for prescription drugs.

But in May, the administration abandoned a proposal to allow private Medicare plans to refuse to pay for certain drugs in so-called “protected classes” if they spiked in price. Earlier this week, a federal judge blocked its regulation that would have required drug makers to include list prices in ads. And on Wednesday, the administration pulled the plug on its effort to ban many of the rebates that drug companies pay to pharmacy benefit managers under Medicare.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • This is probably the stupidest move our great President Trump has made ! Tell me what he does not see regarding how the PBM’s do business ? Your telling me Alex Azar doesn’t know how the PBM’s work ? He was the CEO of Eli Lilly …. He paid those so called drug rebates to get proper placement on the drug formularies .
    Gee, I wonder why they call it a drug rebate when its the determination factor for getting on formulary?
    He really thinks that an International price index is going to be the answer ? What a Fu_kin joke !!!!
    I heard the PBM’s had a huge party today !!!! What a disaster !!!!!!!!!

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy